DeCure for Fanconi anemia complementation group D1
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi anemia complementation group D1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi anemia complementation group D1 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi anemia complementation group d1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BRCA2 DNA repair associated (BRCA2) — BRCA2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8PBC · 2.61 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
Fanconi anemia complementation group D1 is not directly studied in any of the provided abstracts. The abstracts describe Fanconi anemia generally, with specific genetic data for groups A and C only. One 1997 study screened 97 racially and ethnically diverse patients from the International Fanconi Anemia Registry for mutations in the FAA (group A) gene, finding 45 benign polymorphisms and 40 likely pathogenic mutations. Two deletions (1115-1118del and 3788-3790del) were carried on about 2% and 5% of FA alleles respectively among 350 probands. The 3788-3790del appeared in multiple ethnic groups and on at least two haplotypes. The authors suggest FAA is hypermutable, with slipped-strand mispairing as a major mutational mechanism.
A 1999 review states that Fanconi anemia is a rare autosomal recessive disease with mean age of anaemia onset at 8 years and mean survival of 16 years, with death usually from bone marrow failure complications. A 2016 review notes that the molecular mechanism underlying bone marrow failure has remained elusive and is still debated. A 1998 review reports that transfection of the normal FA gene into mutant cells corrects hypersensitivity to DNA cross-linking agents and improves cell viability in vitro, and that an experimental gene therapy trial for group C was ongoing at the National Institutes of Health for patients lacking a compatible bone marrow donor.
A 2023 literature review states that Fanconi anemia is caused by biallelic inactivating mutations in more than 20 genes, and that current treatment relies on stem cell transplantation for anaemia correction. It notes that modern and more efficient therapies need to be developed to improve patients’ quality of life. No abstract provides any data specific to complementation group D1, no drug treatment is tested or proposed in any of these papers, and no survival or response rates for any therapy are given for any Fanconi anemia subgroup. What is still missing for group D1 specifically is any direct genetic or clinical data, any targeted therapy, any trial design, and any patient stratification based on the D1 mutation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Proceedings of the National Academy of Sciences · 1997 · 120 citations
Sequence variation in the Fanconi anemia gene <i>FAA</i>
AbstractFanconi anemia (FA) is a genetically heterogeneous autosomal recessive syndrome associated with chromosomal instability, hypersensitivity to DNA crosslinking agents, and predisposition to malignancy. The gene for FA complementation group A (FAA) recently has been cloned. The cDNA is predicted to encode a polypeptide of 1,455 amino acids, with no homologies to any known protein that might suggest a function for FAA. We have used single-strand conformational polymorphism analysis to screen genomic DNA from a panel of 97 racially and ethnically diverse FA patients from the International Fanconi Anemia Registry for mutations in the FAA gene. A total of 85 variant bands were detected. Forty-five of the variants are probably benign polymorphisms, of which nine are common and can be used for various applications, including mapping studies for other genes in this region of chromosome 16q. Amplification refractory mutation system assays were developed to simplify their detection. Forty variants are likely to be pathogenic mutations. Seventeen of these are microdeletions/microinsertions associated with short direct repeats or homonucleotide tracts, a type of mutation thought to be generated by a mechanism of slipped-strand mispairing during DNA replication. A screening of 350 FA probands from the International Fanconi Anemia Registry for two of these deletions (1115-1118del and 3788-3790del) revealed that they are carried on about 2% and 5% of the FA alleles, respectively. 3788-3790del appears in a variety of ethnic groups and is found on at least two different haplotypes. We suggest that FAA is hypermutable, and that slipped-strand mispairing, a mutational mechanism recognized as important for the generation of germ-line and somatic mutations in a variety of cancer-related genes, including p53, APC, RB1, WT1, and BRCA1, may be a major mechanism for FAA mutagenesis.
Current Opinion in Hematology · 1999 · 33 citations
The molecular and cellular biology of Fanconi anemia
AbstractFanconi anemia is a rare autosomal recessive disease characterized by multiple congenital abnormalities, bone marrow failure, and cancer susceptibility. The mean age of onset of anemia is 8 years, and the mean survival is 16 years. Death usually results from complications of bone marrow failure. Considerable progress in Fanconi anemia research has resulted from the recent identification and cloning of three Fanconi anemia genes. The current review describes the structure and function of the Fanconi anemia genes and describes the role of the encoded Fanconi anemia proteins in a cellular pathway controlling chromosome stability.
TGF-β: a master regulator of the bone marrow failure puzzle in Fanconi anemia
AbstractFanconi anemia (FA) is a genetic disease mainly characterized by progressive bone marrow failure (BMF), congenital abnormalities, and increased predisposition to cancer (1,2). Although most patients with FA develop BMF generally during childhood, the molecular mechanism underlying BMF has remained elusive for a long time and is still a matter of debate.
Anales del Sistema Sanitario de Navarra · 2009 · 3 citations · open access
Updating Fanconi's anaemia
AbstractFanconi's anaemia (FA) is an autosomal recessive syndrome associated with chromosomal instability, and hypersensitivity of the DNA to claustrogenic agents. Clinically it presents a progressive marrow insufficiency, different congenital anomalies and an predisposition to malignancy. Eight complementation groups have been defined and the genes corresponding to six of them have been cloned. Recent advances in molecular biology have made it possible to investigate the relationship between the FA genotype and the nature and severity of the clinical phenotype. The treatment of FA is also the object of intense research that is currently centred on the transplant of hematopoyetic progenitors, especially successful in cases of an HLA-identical brother or sister donor, and in gene therapy, which is still in the phase of clinical research.
The Keio Journal of Medicine · 1998 · 0 citations · open access
Molecular Approaches to the Treatment of Fanconi Anemia: Recent Advances.
AbstractFanconi anemia (FA) is an autosomal recessive disorder that leads to aplastic anemia. Cells from FA patients are abnormally sensitive to DNA cross-linking agents such as mitomycin C. FA consists of at least five subgroups (FA-A through-E). The genes defective in the FA-C and FA-A groups have recently been cloned. Transfection of the normal FA gene into mutant cells corrects the hypersensitivity to DNA cross-linking agents and improves cell viability in vitro. The function of the FA gene products is still unclear, however. For patients lacking a compatible bone marrow transplantation donor, an experimental trial of gene therapy for group C FA is ongoing at the National Institutes of Health.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Current and Novel Directions in Fanconi Anemia Treatment Methods - a Literature Review
AbstractFanconi anemia is a genetically-transmitted disease caused by biallelic inactivating mutations in more than 20 genes. While its main symptoms include severe anemia, other cytopenias and skin pigmentation impairments, the aspect which concerns both patients and caregivers is the connection between Fanconi anemia and the development of several malignancies, especially breast, skin and blood-related cancers, as well as squamous cell carcinomas. Current treatment methods rely on anemia correction through stem cell transplantation, however it has become more and more evident that modern and more efficient therapies need to be developed. This needs-led literature review provides an overview of the main highlights in Fanconi anemia current and emerging therapeutic directions in order to improve the patients’ quality of life.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
